Bharat Biotech seeks DCGI nod for phase-3 study of intranasal Covid vaccine in 5-18 age group
iNCOVACC is a recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilised spike protein. This vaccine candidate was evaluated in phase 1, 2 and 3 clinical trials with successful results, a release from the vaccine-maker said.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Adenoviruses | Biotechnology | Clinical Trials | Covid Vaccine | Pharmaceuticals | Study | Vaccines